SCHEMBL11962066

SCHEMBL11962066

CNC(COC)C(=O)OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.39
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA14 Q9ULX7 2/20 0.35
CA12 O43570 1/20 0.35
CA3 P07451 1/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35
CA5A P35218 1/20 0.35
CA7 P43166 1/20 0.35
CACNA1C Q13936 1/20 0.35
SCN9A Q15858 1/20 0.35
CA9 Q16790 1/20 0.35
CA13 Q8N1Q1 1/20 0.35
CA5B Q9Y2D0 1/20 0.35
MME P08473 1/20 0.34
ALDH1A1 P00352 2/20 0.34
BIRC2 Q13490 1/20 0.34
THRB P10828 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12155238 1.00 SMN1; SMN2 (0.39) SMN1; SMN2CA1CA2CA14CA12
SCHEMBL14224834 1.00 SMN1; SMN2 (0.39) SMN1; SMN2CA1CA2CA14CA12
SCHEMBL23177802 0.84 CAD (0.42) SMN1; SMN2CA1CA2CA14CA12
SCHEMBL23419990 0.84 CA1 (0.35) SMN1; SMN2CA1CA2TAS1R3TAS1R1
SCHEMBL22859885 0.84 CAD (0.42) SMN1; SMN2CA1CA2CA14CA12
SCHEMBL19546005 0.83
SCHEMBL2600862 0.83
SCHEMBL516204 0.83
SCHEMBL8164719 0.83
SCHEMBL19487354 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-18 US disclosed
US-9175027-B2 Polymer-carbohydrate-lipid conjugates LIPOSEUTICALS, INC. 2015-11-03 US disclosed
US-9034798-B2 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions CAPROTEC BIOANALYTICS GMBH (DE) 2015-05-19 US disclosed
US-20120202979-A1 POLYMER-CARBOHYDRATE-LIPID CONJUGATES LIPOSEUTICALS, INC. 2012-08-09 US disclosed
US-20120202890-A1 POLYMER-CARBOHYDRATE-LIPID CONJUGATES WU NIAN (US) 2012-08-09 US disclosed
US-20100298168-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions HK PHARMACEUTICALS, INC. 2010-11-25 US disclosed
US-20100248264-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions HK PHARMACEUTICALS, INC. 2010-09-30 US disclosed
US-20070299263-A1 Hydroxy Alkyl Amines Elan Pharmaceuticals, Inc. and Pharmacia & Upjohn Company 2007-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS SMN1; SMN2 4201/4885CA1 2707/4885CA2 1953/4885
US-20120202890-A1 POLYMER-CARBOHYDRATE-LIPID CONJUGATES LIPC, FUT6, UGCG SMN1; SMN2 4271/4885CA1 1164/4885CA2 1021/4885
US-20070299263-A1 Hydroxy Alkyl Amines MAOA, PSEN2, PSEN1 SMN1; SMN2 492/4885CA1 2672/4885CA2 4612/4885
US-20100298168-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions CHLSN, PTMS, SRMS SMN1; SMN2 3130/4885CA1 2488/4885CA2 3670/4885
US-20120202979-A1 POLYMER-CARBOHYDRATE-LIPID CONJUGATES LIPC, FUT6, UGCG SMN1; SMN2 4271/4885CA1 1164/4885CA2 1021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.